PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
PLx Pharma Inc. (NASDAQ: PLXP) is set to participate in the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021, at 10:00 a.m. ET. Presenters will be Natasha Giordano, CEO, and Rita O’Connor, CFO. The company focuses on its PLxGuard™ technology, which enhances drug absorption and mitigates stomach injury risk. Its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, are FDA-approved aspirin capsules offering targeted release. An archived version of the presentation will be available for 90 days post-event on their website.
- None.
- None.
SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to together as “VAZALORE”), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, are scheduled to present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021.
| Date: | Monday, November 22, 2021 |
| Time/On Demand: | 10:00 a.m. ET |
| Webcast: | https://pipersandler.zoom.us/rec/play/sDoWhmNTPTcs-2ryqdNstA_8p5szMRwpYCiZ4yZZ0mPqzpGwYIvCugpdxgKdwx_QnBUDg8_x68njBqIt.X5bELQj2jSVlI0U3 |
The webcast of the previously recorded presentation will be accessible on demand and archived for 90 days thereafter, via the Company’s website at www.plxpharma.com, under the ‘Investors Relations’ Section.
In conjunction with the Piper Sandler conference, PLx Pharma will also conduct meetings with investors on November 30, 2021. Meetings can be requested exclusively via Piper Sandler.
About VAZALORE
VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products. The special complex inside the capsule allows for targeted release of aspirin, limiting its direct contact with the stomach. VAZALORE delivers fast, reliable absorption for pain relief plus the lifesaving benefits of aspirin. To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma, Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Forward-Looking Statements
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the prospects for commercializing or selling any products or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to PLx may identify forward-looking statements. PLx cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by PLx to secure and maintain relationships with collaborators; risks relating to clinical trials; risks relating to the commercialization, if any, of PLx’s proposed product candidates (such as marketing, regulatory, product liability, supply, competition, and other risks); dependence on the efforts of third parties; dependence on intellectual property, risks that PLx may lack the financial resources and access to capital to fund proposed operations. Further information on the factors and risks that could affect PLx’s business, financial conditions and results of operations are contained in PLx’s filings with the U.S. Securities and Exchange Commission (“SEC”), which are available at www.sec.gov. Other risks and uncertainties are more fully described in PLx’s Form 10-K for the year ended December 31, 2020 filed with the SEC on March 12, 2021, and in other filings that PLx has made or will make going forward. The forward-looking statements represent PLx’s estimate as of the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What is the focus of PLx Pharma Inc. as mentioned in the press release?
When will PLx Pharma present at the Piper Sandler Healthcare Conference?
Who are the key executives presenting for PLx Pharma at the conference?
What products are highlighted in the PLx Pharma press release?
How long will the webcast of the PLx Pharma presentation be available?
What is VAZALORE and how is it different from traditional aspirin?
